Wrapping up Q2 earnings, we look at the numbers and key takeaways for the senior health, home health & hospice stocks, including Brookdale (NYSE: BKD) and its peers.

The senior health, home care, and hospice care industries provide essential services to aging populations and patients with chronic or terminal conditions. These companies benefit from stable, recurring revenue driven by relationships with patients and families that can extend many months or even years. However, the labor-intensive nature of the business makes it vulnerable to rising labor costs and staffing shortages, while profitability is constrained by reimbursement rates from Medicare, Medicaid, and private insurers. Looking ahead, the industry is positioned for tailwinds from an aging population, increasing chronic disease prevalence, and a growing preference for personalized in-home care. Advancements in remote monitoring and telehealth are expected to enhance efficiency and care delivery. However, headwinds such as labor shortages, wage inflation, and regulatory uncertainty around reimbursement could pose challenges. Investments in digitization and technology-driven care will be critical for long-term success.

The 7 senior health, home health & hospice stocks we track reported a mixed Q2. As a group, revenues missed analysts’ consensus estimates by 0.5%.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 10.6% since the latest earnings results.

Brookdale (NYSE: BKD)

With a network of over 650 communities serving approximately 59,000 residents across 41 states, Brookdale Senior Living (NYSE: BKD) operates senior living communities across the United States, offering independent living, assisted living, memory care, and continuing care retirement communities.

Brookdale reported revenues of $718.6 million, down 11.6% year on year. This print fell short of analysts’ expectations by 2.3%. Overall, it was a mixed quarter for the company with a beat of analysts’ EPS estimates but full-year EBITDA guidance meeting analysts’ expectations.

"We continue to execute on our strategy to optimize Brookdale's operating performance and real estate portfolio for the immense senior housing opportunity ahead of us as the baby boom generation begins to reach age 80," said Nick Stengle, Brookdale's Chief Executive Officer.

Brookdale delivered the slowest revenue growth among its peers. The market seems disappointed with the results as the stock is down 15.4% since reporting and currently trades at $11.59.

Read our full report on Brookdale here, it’s free.

Best Q2: BrightSpring Health Services (NASDAQ: BTSG)

Founded in 1974, BrightSpring Health Services (NASDAQ: BTSG) offers home health care, hospice, neuro-rehabilitation, and pharmacy services.

BrightSpring Health Services reported revenues of $3.87 billion, up 23% year on year, outperforming analysts’ expectations by 5.9%. The business had a very strong quarter with a beat of analysts’ EPS estimates and full-year revenue guidance slightly topping analysts’ expectations.

BrightSpring Health Services delivered the biggest analyst estimate beat of the whole group. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 22.3% since reporting. It currently trades at $56.62.

Is now the time to buy BrightSpring Health Services? Access our full analysis of the earnings results here, it’s free.

Weakest Q2: AdaptHealth (NASDAQ: AHCO)

With a network of approximately 680 locations serving patients across all 50 states, AdaptHealth (NASDAQ: AHCO) provides home medical equipment, supplies, and related services to patients with chronic conditions like sleep apnea, diabetes, and respiratory disorders.

AdaptHealth reported revenues of $740.3 million, up 12.7% year on year, falling short of analysts’ expectations by 12.6%. It was a disappointing quarter as it posted full-year revenue guidance missing analysts’ expectations significantly and full-year EBITDA guidance missing analysts’ expectations significantly.

AdaptHealth delivered the weakest performance against analyst estimates and weakest full-year guidance update among its peers. As expected, the stock is down 46.5% since the results and currently trades at $5.80.

Read our full analysis of AdaptHealth’s results here.

Chemed (NYSE: CHE)

With a unique business model combining end-of-life care and household services, Chemed (NYSE: CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services.

Chemed reported revenues of $673.3 million, up 8.8% year on year. This number beat analysts’ expectations by 1.2%. Overall, it was a very strong quarter as it also recorded an impressive beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.

The stock is down 2.3% since reporting and currently trades at $505.97.

Read our full, actionable report on Chemed here, it’s free.

The Pennant Group (NASDAQ: PNTG)

Spun off from The Ensign Group in 2019 to focus on non-skilled nursing healthcare services, Pennant Group (NASDAQ: PNTG) operates home health, hospice, and senior living facilities across 13 western and midwestern states, serving patients of all ages including seniors.

The Pennant Group reported revenues of $295.8 million, up 36.3% year on year. This print topped analysts’ expectations by 2.5%. It was a very strong quarter as it also put up full-year revenue guidance slightly topping analysts’ expectations and a beat of analysts’ EPS estimates.

The Pennant Group delivered the fastest revenue growth and highest full-year guidance raise in the group. The stock is up 2.7% since reporting and currently trades at $39.88.

Read our full, actionable report on The Pennant Group here, it’s free.

Market Update

Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.

Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.

By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.

Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.